Background Intrahepatic cholangiocarcinoma (iCCA) is characterized by marked molecular and microenvironmental heterogeneity and moderate response to immunotherapy. We aimed to define the genomic and spatial determinants of immune checkpoint activity in iCCA and their association with clinical outcome. Methods We perfor...
A. Korosteleva, J. Reschke, Da-Wei Yi et al.· Hepatology Communications· 0 citations
The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.
M. Persano, A. Casadei-Gardini, L. Fornaro et al.· Cancer· 0 citations
The evolving therapeutic landscape, emphasizing clinical efficacy, and indications for various treatment modalities are reviewed, with a focus on on-target mutations and convergent off-target MAPK signaling pathways.
L. Aceituno, E. Valenzi, O. Segatto et al.· Seminars in Cancer Biology· 0 citations
It is shown that ML models integrating biliary-disease associated health records and Gamma glutamyltransferase can stratify risk of future CCA, and demonstrates the potential of data-driven models in personalised screening for hepatobiliary cancer.
F. van Haag, J. Clusmann, Paul-Henry Koop et al.· EBioMedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.